VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration aimed at developing next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. The early in vitro studies showed that an AOC candidate combining the companies' technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of this approach to selectively deliver therapeutic oligonucleotides to disease-specific cells.
This collaboration marks a significant step for VERAXA, as it demonstrates the potential application of its proprietary click chemistry-powered conjugation technology beyond its primary focus on solid tumors. The companies are currently discussing next steps in the collaboration, which could lead to further preclinical development and eventual clinical trials.
The positive results underscore the growing interest in AOCs as a therapeutic modality, which combine the targeting capabilities of antibodies with the gene-silencing or gene-modulating effects of oligonucleotides. By delivering oligonucleotides specifically to disease-associated cells, AOCs hold promise for improving efficacy and reducing off-target effects compared to systemic oligonucleotide delivery.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development.
Secarna Pharmaceuticals is a leader in the discovery and development of novel antisense oligonucleotide therapies, with a focus on addressing high unmet medical needs in autoimmune, inflammatory, and oncologic diseases. The collaboration leverages Secarna's expertise in oligonucleotide design and VERAXA's advanced conjugation technology to create targeted therapeutics.
The announcement is noteworthy for the biotech industry as it validates the utility of click chemistry in creating stable and functional conjugates, which could pave the way for more precise treatments in immune-mediated conditions. Investors and stakeholders will be watching closely as the collaboration progresses, with further data expected to clarify the potential of this approach.
For more details on the press release, visit https://ibn.fm/IF9Cy. To stay updated on VERAXA's latest news, see their newsroom at http://ibn.fm/VRXA.
